9月24日，Viking Therapeutics盘中下跌14.12%，报36.01美元/股，成交额1.5亿美元。
消息面上，公司宣布分别发行2亿美元普通股及2亿美元于2032年到期的可转换优先票据，并授予承销商30天超额配售选择权（各最高3000万美元），融资净收益将用于VK2735及VK3019项目的临床开发与商业化推进。此前，公司公布GLP-1/GIP双激动剂VK2735维持期研究积极数据，隔周给药方案下患者维持高达97%的减重效果，9月22日单日大涨逾34%。在股价连续大幅上涨后，双重发行带来的股权稀释压力叠加获利回吐情绪，共同推动股价显著回落。
Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法，VK2735为其主要肥胖症候选药物，正开发注射剂和口服剂两种剂型。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.